This company is no longer active
Otonomy (7OT) Stock Overview
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
7OT Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Otonomy, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.063 |
| 52 Week High | US$2.33 |
| 52 Week Low | US$0.022 |
| Beta | 1.53 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -96.91% |
| 3 Year Change | -96.60% |
| 5 Year Change | -98.00% |
| Change since IPO | -99.48% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7OT | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | 4.3% | 3.4% |
| 1Y | -96.9% | 22.3% | 8.1% |
Return vs Industry: 7OT underperformed the German Pharmaceuticals industry which returned -13.2% over the past year.
Return vs Market: 7OT underperformed the German Market which returned -7% over the past year.
Price Volatility
| 7OT volatility | |
|---|---|
| 7OT Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 4.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in DE Market | 13.8% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: 7OT has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 7OT's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 51 | n/a | www.otonomy.com |
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. It also develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss.
Otonomy, Inc. Fundamentals Summary
| 7OT fundamental statistics | |
|---|---|
| Market cap | €530.12k |
| Earnings (TTM) | -€47.56m |
| Revenue (TTM) | n/a |
Is 7OT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7OT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$52.26m |
| Earnings | -US$52.26m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.76 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 75.4% |
How did 7OT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/04/13 02:12 |
| End of Day Share Price | 2023/01/18 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Otonomy, Inc. is covered by 9 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Aaron Gal | Bernstein |
| Sumant Satchidanand Kulkarni | BofA Global Research |
| Charles Duncan | Cantor Fitzgerald & Co. |